Literature DB >> 29695756

Disease-causing variants in TCF4 are a frequent cause of intellectual disability: lessons from large-scale sequencing approaches in diagnosis.

Laura Mary1, Amélie Piton2,3, Elise Schaefer4, Francesca Mattioli5,6, Elsa Nourisson1, Claire Feger1, Claire Redin5,6, Magali Barth7, Salima El Chehadeh4,8, Estelle Colin7, Christine Coubes9, Laurence Faivre8, Elisabeth Flori4, David Geneviève9, Yline Capri10, Laurence Perrin10, Jennifer Fabre-Teste10, Dana Timbolschi4, Alain Verloes10, Robert Olaso11, Anne Boland11, Jean-François Deleuze11, Jean-Louis Mandel1,5,6, Bénédicte Gerard1, Irina Giurgea12,13.   

Abstract

High-throughput sequencing (HTS) of human genome coding regions allows the simultaneous screen of a large number of genes, significantly improving the diagnosis of non-syndromic intellectual disabilities (ID). HTS studies permit the redefinition of the phenotypical spectrum of known disease-causing genes, escaping the clinical inclusion bias of gene-by-gene Sanger sequencing. We studied a cohort of 903 patients with ID not reminiscent of a well-known syndrome, using an ID-targeted HTS of several hundred genes and found de novo heterozygous variants in TCF4 (transcription factor 4) in eight novel patients. Piecing together the patients from this study and those from previous large-scale unbiased HTS studies, we estimated the rate of individuals with ID carrying a disease-causing TCF4 mutation to 0.7%. So far, TCF4 molecular abnormalities were known to cause a syndromic form of ID, Pitt-Hopkins syndrome (PTHS), which combines severe ID, developmental delay, absence of speech, behavioral and ventilation disorders, and a distinctive facial gestalt. Therefore, we reevaluated ten patients carrying a pathogenic or likely pathogenic variant in TCF4 (eight patients included in this study and two from our previous ID-HTS study) for PTHS criteria defined by Whalen and Marangi. A posteriori, five patients had a score highly evocative of PTHS, three were possibly consistent with this diagnosis, and two had a score below the defined PTHS threshold. In conclusion, these results highlight TCF4 as a frequent cause of moderate to profound ID and broaden the clinical spectrum associated to TCF4 mutations to nonspecific ID.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29695756      PMCID: PMC6018712          DOI: 10.1038/s41431-018-0096-4

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  33 in total

1.  Parent-child exome sequencing identifies a de novo truncating mutation in TCF4 in non-syndromic intellectual disability.

Authors:  F F Hamdan; H Daoud; L Patry; A Dionne-Laporte; D Spiegelman; S Dobrzeniecka; G A Rouleau; J L Michaud
Journal:  Clin Genet       Date:  2012-06-04       Impact factor: 4.438

2.  The fragile X prevalence paradox.

Authors:  Paul J Hagerman
Journal:  J Med Genet       Date:  2008-04-15       Impact factor: 6.318

3.  Mutations in TCF4, encoding a class I basic helix-loop-helix transcription factor, are responsible for Pitt-Hopkins syndrome, a severe epileptic encephalopathy associated with autonomic dysfunction.

Authors:  Jeanne Amiel; Marlene Rio; Loic de Pontual; Richard Redon; Valerie Malan; Nathalie Boddaert; Perrine Plouin; Nigel P Carter; Stanislas Lyonnet; Arnold Munnich; Laurence Colleaux
Journal:  Am J Hum Genet       Date:  2007-03-23       Impact factor: 11.025

4.  Haploinsufficiency of TCF4 causes syndromal mental retardation with intermittent hyperventilation (Pitt-Hopkins syndrome).

Authors:  Christiane Zweier; Maarit M Peippo; Juliane Hoyer; Sergio Sousa; Armand Bottani; Jill Clayton-Smith; William Reardon; Jorge Saraiva; Alexandra Cabral; Ina Gohring; Koen Devriendt; Thomy de Ravel; Emilia K Bijlsma; Raoul C M Hennekam; Alfredo Orrico; Monika Cohen; Alexander Dreweke; Andre Reis; Peter Nurnberg; Anita Rauch
Journal:  Am J Hum Genet       Date:  2007-03-23       Impact factor: 11.025

5.  B-lymphocyte development is regulated by the combined dosage of three basic helix-loop-helix genes, E2A, E2-2, and HEB.

Authors:  Y Zhuang; P Cheng; H Weintraub
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

6.  Partial deletion of TCF4 in three generation family with non-syndromic intellectual disability, without features of Pitt-Hopkins syndrome.

Authors:  Mira Kharbanda; Kaja Kannike; Anne Lampe; Jonathan Berg; Tõnis Timmusk; Mari Sepp
Journal:  Eur J Med Genet       Date:  2016-04-28       Impact factor: 2.708

7.  Disruption of the TCF4 gene in a girl with mental retardation but without the classical Pitt-Hopkins syndrome.

Authors:  Vera M Kalscheuer; Ilse Feenstra; Conny M A Van Ravenswaaij-Arts; Dominique F C M Smeets; Corinna Menzel; Reinhard Ullmann; Luciana Musante; Hans-Hilger Ropers
Journal:  Am J Med Genet A       Date:  2008-08-15       Impact factor: 2.802

8.  Targeted Next-Generation Sequencing Analysis of 1,000 Individuals with Intellectual Disability.

Authors:  Detelina Grozeva; Keren Carss; Olivera Spasic-Boskovic; Maria-Isabel Tejada; Jozef Gecz; Marie Shaw; Mark Corbett; Eric Haan; Elizabeth Thompson; Kathryn Friend; Zaamin Hussain; Anna Hackett; Michael Field; Alessandra Renieri; Roger Stevenson; Charles Schwartz; James A B Floyd; Jamie Bentham; Catherine Cosgrove; Bernard Keavney; Shoumo Bhattacharya; Matthew Hurles; F Lucy Raymond
Journal:  Hum Mutat       Date:  2015-09-30       Impact factor: 4.878

9.  Prevalence and architecture of de novo mutations in developmental disorders.

Authors: 
Journal:  Nature       Date:  2017-01-25       Impact factor: 49.962

10.  Phenotype and natural history in 101 individuals with Pitt-Hopkins syndrome through an internet questionnaire system.

Authors:  Channa F de Winter; Melanie Baas; Emilia K Bijlsma; John van Heukelingen; Sue Routledge; Raoul C M Hennekam
Journal:  Orphanet J Rare Dis       Date:  2016-04-12       Impact factor: 4.123

View more
  5 in total

1.  Repurposing the Dihydropyridine Calcium Channel Inhibitor Nicardipine as a Nav1.8 Inhibitor In Vivo for Pitt Hopkins Syndrome.

Authors:  Sean Ekins; Ana C Puhl; Audrey Davidow
Journal:  Pharm Res       Date:  2020-06-11       Impact factor: 4.200

2.  Recommendations by the ClinGen Rett/Angelman-like expert panel for gene-specific variant interpretation methods.

Authors:  Dianalee McKnight; Lora Bean; Izabela Karbassi; Katelynn Beattie; Thierry Bienvenu; Hope Bonin; Ping Fang; John Chrisodoulou; Michael Friez; Maria Helgeson; Rahul Krishnaraj; Linyan Meng; Lindsey Mighion; Jeffrey Neul; Alan Percy; Simon Ramsden; Huda Zoghbi; Soma Das
Journal:  Hum Mutat       Date:  2021-12-02       Impact factor: 4.700

3.  Enriched environment ameliorates adult hippocampal neurogenesis deficits in Tcf4 haploinsufficient mice.

Authors:  Katharina Braun; Benjamin M Häberle; Marie-Theres Wittmann; D Chichung Lie
Journal:  BMC Neurosci       Date:  2020-11-23       Impact factor: 3.288

4.  Region and Cell Type Distribution of TCF4 in the Postnatal Mouse Brain.

Authors:  Hyojin Kim; Noah C Berens; Nicole E Ochandarena; Benjamin D Philpot
Journal:  Front Neuroanat       Date:  2020-07-17       Impact factor: 3.856

5.  Pitt-Hopkins Syndrome: Clinical and Molecular Findings of a 5-Year-Old Patient.

Authors:  Florin Tripon; Alina Bogliș; Cristian Micheu; Ioana Streață; Claudia Bănescu
Journal:  Genes (Basel)       Date:  2020-05-28       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.